← Leaderboards
David Peter Cormode
Icahn School Of Medicine At Mount Sinai
$8,115,709
Attributed
$8,115,709
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,115,709 · 11
By mechanism
R01$5,562,255 · 4
R21$1,285,471 · 3
R00$706,227 · 1
R41$223,028 · 1
K99$178,728 · 1
R03$160,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoNanoparticleIn VitroPublic Health RelevanceContrast MediaPropertyBiologicalBaseFormulationImageBiomaterial CompatibilityRoentgen RaysMagnetic Resonance ImagingKidneyPolymersLeadBloodImaging TechniquesExcretory FunctionMalignant NeoplasmsToxic EffectBlood CirculationSmall MoleculeOrgan
Grant awards (26)
Silver Telluride Nanoparticle Dual-Energy Mammography Contrast Agents For Breast Cancer Screening$554,188
R01 · FY2025 · CA · contact PI
Cerium oxide nanoparticles for CT imaging and catalytic therapeutic intervention in inflammatory bowel disease$545,290
R01 · FY2025 · EB · contact PI
Enhanced treatment of breast cancer via biodegradable polymer nanoparticles$391,826
R21 · FY2025 · CA · contact PI
Nanoparticle contrast agents for earlier breast cancer detection$439,409
R01 · FY2022 · CA · contact PI
Renally clearable ytterbium nanoparticle contrast agents for spectral photon counting computed tomography$243,750
R21 · FY2022 · EB · contact PI
Tumor casting hydrogels for interventional radiology treatment of hepatocellular carcinoma$243,750
R21 · FY2022 · EB · contact PI
Nanoparticle contrast agents for earlier breast cancer detection$524,525
R01 · FY2021 · CA · contact PI
Renally clearable ytterbium nanoparticle contrast agents for spectral photon counting computed tomography$203,125
R21 · FY2021 · EB · contact PI
Tumor casting hydrogels for interventional radiology treatment of hepatocellular carcinoma$203,020
R21 · FY2021 · EB · contact PI
Nanoparticle contrast agents for earlier breast cancer detection$524,367
R01 · FY2020 · CA · contact PI
Biodegradable polymetal nanoparticle CT contrast agents for vascular imaging$400,000
R01 · FY2020 · HL · contact PI
Nanoparticle contrast agents for earlier breast cancer detection$434,923
R01 · FY2019 · CA · contact PI
Biodegradable polymetal nanoparticle CT contrast agents for vascular imaging$400,000
R01 · FY2019 · HL · contact PI
Nanoparticle contrast agents for earlier breast cancer detection$75,929
R01 · FY2019 · CA · contact PI
Nanoparticle contrast agents for earlier breast cancer detection$463,624
R01 · FY2018 · CA · contact PI
Biodegradable polymetal nanoparticle CT contrast agents for vascular imaging$400,000
R01 · FY2018 · HL · contact PI
Biodegradable polymetal nanoparticle CT contrast agents for vascular imaging$400,000
R01 · FY2017 · HL · contact PI
Biodegradable gold nanoparticles as contrast agents for CT$223,028
R41 · FY2017 · EB · contact PI
Biodegradable polymetal nanoparticle CT contrast agents for vascular imaging$400,000
R01 · FY2016 · HL · contact PI
Macrophage COX-2 as a target in breast cancer chemoprevention$80,000
R03 · FY2015 · CA · contact PI
Theranostic Nanoparticles to enhance morpholino delivery to the liver for suppres$228,619
R00 · FY2014 · EB · contact PI
Macrophage COX-2 as a target in breast cancer chemoprevention$80,000
R03 · FY2014 · CA · contact PI
Theranostic Nanoparticles to enhance morpholino delivery to the liver for suppres$228,624
R00 · FY2013 · EB · contact PI
Theranostic Nanoparticles to enhance morpholino delivery to the liver for suppres$248,984
R00 · FY2012 · EB · contact PI
Theranostic nanoparticles to enhance morpholino delivery to the liver for suppres$89,364
K99 · FY2011 · EB · contact PI
Theranostic nanoparticles to enhance morpholino delivery to the liver for suppres$89,364
K99 · FY2010 · EB · contact PI